Consistent with the tumor responses, EGFR‐19del LLC tumors contain significantly lower numbers of CD11c+MHC‐II+ DCs (Figure 2e,f), which express reduced levels of CD80 and CD86, than the WT tumors (Figure 2g). This evidence concerns the gene ITGAX and neoplasm.